AHR
American Healthcare Reit, Inc. Real Estate Real Estate Investment Trusts Russell 3000
$53.52Close
$9.9BMarket cap
$44.61 – $57.7252-week range
Nov 5, 2026Next report · after the close
Highlights
Strengths
- Earnings growing EPS +157% year on year
Cautions
- Trend not confirmed 6 of 8 conditions · under 30% off the low, RS under 70
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
7%
1wk
up 0.9%
price change
1mo
up 4.4%
price change
12-month return
up 20%
market up 11% ·
its own up 11%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
140.5×
price / earnings
PEG
—
P/E / EPS growth
P/B
3.0×
price / book
Earnings yield
up 3.8%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
up 11%
year on year
EPS growth
up 157%
latest quarter
Sales growth
up 27%
latest quarter · +4 pts
ROE
up 3%
return on equity
Free cash margin
up 14%
$294.4M FCF
D/E
0.30
long-term debt / equity
Net debt / EBITDA
1.4×
Interest cover
4.8×EBIT / interest
Piotroski tests
Repair signals
- Gross margin 12.2% → 14.4%
Trade setup
ATR%
2.7%
$1.42 a day · 2×ATR $50.68
RS
58 / 99
vs the universe
Trend
6 / 8
under 30% off the low, RS under 70
Relative volume
0.9×
vs 50-day average
Up/down volume
1.03
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 6 of 8
- At least 30% above the 52-week low: fails
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- No restatement or impairment
- Equity positive
- Interest covered
- No material dilution
- Profits tracking cash
- Margins and revenue not shrinking
Last reported
Aug 6, 2026
Results reaction
Aug 6, 2026+2% vs market2 sessions after results
Financials
- Gross 14%
- Net 3%
- Free cash 14%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.1B | $1.1B | $1.4B | $1.7B | $1.9B | $2.1B |
| Gross margin | 7% | 8% | 9% | 10% | 12% | 14% |
| Operating income | $218.3M | $213.3M | $302.0M | $306.8M | $363.5M | $415.2M |
| Net income | $2.2M | -$53.3M | -$73.4M | -$76.9M | -$35.6M | $70.8M |
| Net margin | 0% | -5% | -5% | -5% | -2% | 3% |
| Earnings per share | $0.05 | -$1.06 | -$1.12 | -$1.16 | -$0.27 | $0.42 |
| Free cash flow | $219.2M | $17.9M | $147.8M | $98.5M | $176.1M | $294.4M |
| Free cash margin | 20% | 2% | 10% | 6% | 9% | 14% |
| Cash | $113.2M | $81.6M | $65.1M | $43.4M | $76.7M | $114.8M |
| Long-term debt | $834.0M | $1.1B | $1.3B | $1.3B | $1.0B | $985.6M |
| Shareholders' equity | $866.1M | $1.6B | $1.4B | $1.3B | $2.3B | $3.3B |
| Shares outstanding | 179.66m | — | — | — | — | 185.91m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 7, 2026 | Quarterly ↗ | Jun 30, 2026 | 38d |
| May 8, 2026 | Quarterly ↗ | Mar 31, 2026 | 38d |
| Feb 27, 2026 | Annual ↗ | Dec 31, 2025 | 58d |
| Nov 7, 2025 | Quarterly ↗ | Sep 30, 2025 | 38d |
| Aug 8, 2025 | Quarterly ↗ | Jun 30, 2025 | 39d |
| May 9, 2025 | Quarterly ↗ | Mar 31, 2025 | 39d |
| Feb 28, 2025 | Annual ↗ | Dec 31, 2024 | 59d |
| Nov 13, 2024 | Quarterly ↗ | Sep 30, 2024 | 44d |
| Aug 9, 2024 | Quarterly ↗ | Jun 30, 2024 | 40d |
| May 14, 2024 | Quarterly ↗ | Mar 31, 2024 | 44d |
| Mar 22, 2024 | Annual ↗ | Dec 31, 2023 | 82d |
| Nov 13, 2023 | Quarterly ↗ | Sep 30, 2023 | 44d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 18, 2026 | Regulation FD · Other events ↗ |
| Sep 14, 2026 | Regulation FD ↗ |
| Sep 2, 2026 | Director or officer change · Regulation FD ↗ |
| Sep 1, 2026 | Regulation FD ↗ |
| Aug 24, 2026 | Other events ↗ |
| Aug 12, 2026 | Other events ↗ |
| Aug 10, 2026 | Material agreement ↗ |
| Aug 6, 2026 | Results · Regulation FD ↗ |
| Jul 22, 2026 | Director or officer change · Regulation FD ↗ |
| Jun 25, 2026 | Shareholder vote ↗ |
| Jun 18, 2026 | Regulation FD · Other events ↗ |
| May 28, 2026 | Other events ↗ |